Sacubitril is a neprilysin inhibitor used in combination with valsartan to treat chronic heart failure with reduced ejection fraction. As a prodrug, sacubitril is converted to its active metabolite, sacubitrilat,… Read more
![Chemical structure of Isopropyl (2R,4S)-5-([1,1'-biphenyl]-4-yl)-4-(2,5-dioxopyrrolidin-1-yl)-2-methylpentanoate](/_next/image?url=https%3A%2F%2Fassets.splendidlab.com%2F2459446-55-8-Isopropyl-2R4S-5-11-biphenyl-4-yl-4-25-dioxopyrrolidin-1-yl-2-methylpentanoate.png&w=3840&q=75)
![Chemical structure of Isopropyl 4-((3R,5S)-5-([1,1'-biphenyl]-4-ylmethyl)-3-methyl-2-oxopyrrolidin-1-yl)-4-oxobutanoate](/_next/image?url=https%3A%2F%2Fassets.splendidlab.com%2F2149600-13-3-Isopropyl-4-3R5S-5-11-biphenyl-4-ylmethyl-3-methyl-2-oxopyrrolidin-1-yl-4-oxobutanoate.png&w=3840&q=75)
![Chemical structure of Methyl (2R,4S)-5-([1,1'-biphenyl]-4-yl)-4-(2,5-dioxopyrrolidin-1-yl)-2-methylpentanoate](/_next/image?url=https%3A%2F%2Fassets.splendidlab.com%2FMethyl-2R4S-5-11-biphenyl-4-yl-4-25-dioxopyrrolidin-1-yl-2-methylpentanoate.png&w=3840&q=75)
![Chemical structure of Methyl (2R,4S)-5-([1,1'-biphenyl]-4-yl)-4-amino-2-methylpentanoate Hydrochloride](/_next/image?url=https%3A%2F%2Fassets.splendidlab.com%2F1933501-50-8-Methyl-2R4S-5-11-biphenyl-4-yl-4-amino-2-methylpentanoate-Hydrochloride.png&w=3840&q=75)
![Chemical structure of Methyl (E)-5-([1,1'-biphenyl]-4-yl)-2-methyl-4-oxopent-2-enoate](/_next/image?url=https%3A%2F%2Fassets.splendidlab.com%2FMethyl-E-5-11-biphenyl-4-yl-2-methyl-4-oxopent-2-enoate.png&w=3840&q=75)

![Chemical structure of Methyl (R)-3-([1,1'-biphenyl]-4-yl)-2-((tert-butoxycarbonyl)amino)propanoate](/_next/image?url=https%3A%2F%2Fassets.splendidlab.com%2F149818-98-4-Methyl-R-3-11-biphenyl-4-yl-2-tert-butoxycarbonylaminopropanoate.png&w=3840&q=75)
![Chemical structure of Methyl (R)-3-([1,1'-biphenyl]-4-yl)-2-acetamidopropanoate](/_next/image?url=https%3A%2F%2Fassets.splendidlab.com%2F164460-67-7-Methyl-R-3-11-biphenyl-4-yl-2-acetamidopropanoate.png&w=3840&q=75)
![Chemical structure of Methyl (S)-3-([1,1'-biphenyl]-4-yl)-2-((tert-butoxycarbonyl)amino)propanoate](/_next/image?url=https%3A%2F%2Fassets.splendidlab.com%2F137255-86-8-Methyl-S-3-11-biphenyl-4-yl-2-tert-butoxycarbonylaminopropanoate.png&w=3840&q=75)
![Chemical structure of Methyl (Z)-3-([1,1'-biphenyl]-4-yl)-2-acetamidoacrylate](/_next/image?url=https%3A%2F%2Fassets.splendidlab.com%2F556828-95-6-Methyl-Z-3-11-biphenyl-4-yl-2-acetamidoacrylate.png&w=3840&q=75)
![Chemical structure of Methyl 4-([1,1'-biphenyl]-4-yl)-3-oxobutanoate](/_next/image?url=https%3A%2F%2Fassets.splendidlab.com%2F100160-75-6-Methyl-4-11-biphenyl-4-yl-3-oxobutanoate.png&w=3840&q=75)






![Chemical structure of Propyl (2R,4S)-5-([1,1'-biphenyl]-4-yl)-4-(2,5-dioxopyrrolidin-1-yl)-2-methylpentanoate](/_next/image?url=https%3A%2F%2Fassets.splendidlab.com%2FPropyl-2R4S-5-11-biphenyl-4-yl-4-25-dioxopyrrolidin-1-yl-2-methylpentanoate.png&w=3840&q=75)
![Chemical structure of rel-4-((3R,5S)-5-([1,1'-Biphenyl]-4-ylmethyl)-3-methyl-2-oxopyrrolidin-1-yl)-4-oxobutanoic Acid](/_next/image?url=https%3A%2F%2Fassets.splendidlab.com%2F2216746-87-9-rel-4-3R5S-5-11-Biphenyl-4-ylmethyl-3-methyl-2-oxopyrrolidin-1-yl-4-oxobutanoic-Acid.png&w=3840&q=75)
![Chemical structure of rel-Ethyl (2R,4S)-5-([1,1'-biphenyl]-4-yl)-4-(4-ethoxy-4-oxobutanamido)-2-methylpentanoate](/_next/image?url=https%3A%2F%2Fassets.splendidlab.com%2F2216747-18-9-rel-Ethyl-2R4S-5-11-biphenyl-4-yl-4-4-ethoxy-4-oxobutanamido-2-methylpentanoate.png&w=3840&q=75)
![Chemical structure of rel-Ethyl (2R,4S)-5-([1,1'-biphenyl]-4-yl)-4-acetamido-2-methylpentanoate](/_next/image?url=https%3A%2F%2Fassets.splendidlab.com%2F2806120-13-6-rel-Ethyl-2R4S-5-11-biphenyl-4-yl-4-acetamido-2-methylpentanoate.png&w=3840&q=75)
![Chemical structure of rel.4-(((2R,4R)-1-([1,1'-Biphenyl]-4-yl)-5-ethoxy-4-methyl-5-oxopentan-2-yl)amino)-4-oxobutanoic Acid](/_next/image?url=https%3A%2F%2Fassets.splendidlab.com%2F766480-48-2-rel.4-2R4R-1-11-Biphenyl-4-yl-5-ethoxy-4-methyl-5-oxopentan-2-ylamino-4-oxobutanoic-Acid.png&w=3840&q=75)


























Sacubitril is a neprilysin inhibitor used in combination with valsartan to treat chronic heart failure with reduced ejection fraction. As a prodrug, sacubitril is converted to its active metabolite, sacubitrilat, to enhance the effects of natriuretic peptides, helping to reduce cardiac workload and blood pressure. The reference standards for Sacubitril, including its impurities, metabolites, and stable isotope labelled compounds, are critical tools for pharmaceutical laboratories. These materials are essential for conducting rigorous impurity profiling, performing stability-indicating method validation, and ensuring quality control throughout the manufacturing process. By providing high-quality standards that allow for the identification and quantification of synthetic intermediates, process-related by-products, and degradation products, these compounds support regulatory compliance and the maintenance of therapeutic safety. Chemists utilize these reference materials to develop accurate analytical methods, ensuring that every batch meets the stringent requirements for safety and efficacy in clinical applications.